Cardiac hypertrophy and remodelling: Pathophysiological consequences and protective effects of melatonin

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Reiter, Russel J ^a   Manchester, Lucien C ^a   Fuentes Broto, Lorena ^a   Tan, Dun Xian ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

antioxidant; cardiac hypertrophy; cardiomyocytes; heart; left ventricle; melatonin

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; INDOLEAMINE; MELATONIN;

ANTIOXIDANT ACTIVITY; CARDIOMEGALY; CELL DAMAGE; DRUG EFFICACY; DRUG MECHANISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; HYPERTHYROIDISM; HYPOXIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 77957254402     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388488.51083.2b     Document Type: Review

References (52)

1. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 2001; 358:1627-1637.
2. Maron BJ. Hypertrophic cardiomyopathies. Lancet 1997; 350:127-133.
3. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010; 61:269-280.
4. Maron BJ, Shirani J, Poliac LC, Methenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199-204.
5. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens 1999; 12:181S-188S.
6. Tin LL, Beevers DG, Lip GY. Hypertension, left ventricular hypertrophy, and sudden death. Curr Cardiol Rep 2002; 4:449-457.
7. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991; 79:C153-C158.
8. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12:151-180.
9. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44:16-25.
10. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-322.
11. Diez ER, Prados LV, Carrion A, Ponce ZAZ, Miatello RM. A novel electrophysiological effect of melatonin on ischemia/reperfusion-induced arrhythmias in isolated rat hearts. J Pineal Res 2009; 46:155-160.
12. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27:101-110.
13. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74:2227-2236.
14. Boutin JA, Marcheteau E, Hennig P, Moulharat N, Berger S, Delagrange P, et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or as a co-substrate. J Pineal Res 2008; 45:524-531.
15. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997; 64:430-442.
16. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 1998; 12:143-150.
17. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
18. Peyrot C, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008; 45:235-246.
19. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre and postnatal period and the clinical utility of melatonin. J Pineal Res 2009; 46:128-139.
20. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX, Poeggeler B, et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5- methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8:205-213.
21. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47:109-123.
22. Schaefer M, Hardeland R. The melatonin metabolite N1-acetyl-5- methoxykynuramine is a potent singlet oxygen scavenger. J Pineal Res 2009; 46:49-52.
23. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009; 27 (Suppl. 6):S17-S20.
24. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 2009; 47:127-133.
25. O'Brien E, Sheridan J, O'Malley K. Dippers and nondippers. Lancet 1988; 2:397.
26. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43:192-197.
27. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality: the Ohasama study. Am J Hypertens 1997; 10:1201-1207. (Pubitemid 28005341)
28. Girouard H, Denault C, Chulak C, de Champlain J. Treatment with Nacetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve. Am J Hypertens 2004; 17:947-954.
29. Pechanova O, Zicha J, Paulis L, Zenebe W, Dobesova Z, Kojsova S, et al. The effects of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 2007; 561:129-136.
30. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodeling in spontaneously hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S5-S10.
31. Paulis L, Pechanova O, Zicha J, Krajcirovicova K, Barta A, Pelouch V, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricule of NG-nitro-l-arginine-methyl ester hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S11-S16.
32. Ersahin M, Sehirli O, Toklu HZ, Suleymanoglu S, Emekli-Alturfan E, Yarat A, et al. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res 2009; 47:97-106.
33. Ghosh G, De K, Maity S, Bandyopadhyay D, Bhattacharya S, Reiter RJ, et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res 2007; 42:71-82.
34. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/ nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44:175-200.
35. Yeung HM, Hung MW, Fung ML. Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. J Pineal Res 2008; 45:373-382.
36. Flood EM, Kumar RS, Shah R, Amos Q, Wren JD, Shohet RV, et al. Melatonin administration does not affect isoproterenol-induced LVH. IEEE Engin Biol Med Mag 2006; 25:84-87.
37. Mukherjee D, Roy SG, Bandyopadhyay A, Basu A, Mitra E, Ghosh AK, et al. Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J Pineal Res 2010; 48:251-262.
38. Veneraso C, Tunon MJ, Gonzalez-Gallego J, Callado PS. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 2009; 47:184-191.
39. Bertuglia S, Reiter RJ. Melatonin reduces ventricular arrhythmias and preserves capillary perfusion during ischemia-reperfusion events in cardiomyopathic hamsters. J Pineal Res 2007; 42:55-63.
40. Paulis L, Pechanova O, Zicha J, Barta A,Gardlik R, Celec P, et al. Melatonin interactions with blood pressure and vascular function during L-NAMEinduced hypertension. J Pineal Res 2010; 48:102-108.
41. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Reiter RJ, Kaski JC. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010; 49:14-22.
42. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58:10-19.
43. Chen Z, Chua CC, Gao J, Chua KW, Ho YS, Hamdy RC, et al. Prevention of ischemia/reperfusion-induced cardiac apoptosis and injury by melatonin is independent of a glutathione peroxidase 1. J Pineal Res 2009; 46:235-241.
44. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC, Reiter RJ. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 2008; 44:65-69.
45. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol 2009; 7:367-373.
46. Reiter RJ, Tan DX. Melatonin and cardiac pathophysiology. Heart Metab 2009; 44:31-34.
47. Rezzani R, Rodella LF, Fraschini F, Gasco MR, Demartini G, Musicanti G, et al. Melatonin delivery in solid lipid nanoparticles: prevention of cyclosporine A-induced cardiac damage. J Pineal Res 2009; 46:255-261.
48. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.
49. Tan DX, Hardeland R, Manchester LC, Paredes SD, Korkmaz A, Sainz RM, et al. The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol Rev 2010; 85:607-623.
50. Reiter RJ, Richardson BA, Johnson LY, Ferguson BV, Dinh DT. Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science 1980; 210:1372-1373.
51. Reiter RJ, Craft CM, Johnson JE Jr, King TS, Richardson BA, Vaughan GM, et al. Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 1981; 109:1295-1297.
52. Sack RL, Lewy AJ, Erbe DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res 1986; 3:379-388.